Ignite Creation Date:
2024-05-05 @ 5:18 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00424606
Status:
COMPLETED
Last Update Posted:
2015-05-20
First Post:
2007-01-18
Brief Title:
Epirubicin and Docetaxel Combination ET or Epirubicin Followed by Docetaxel ET for Node Negative N0 High Risk Breast Cancer Patients
Sponsor:
Organization:
Hellenic Oncology Research Group
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
658
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE3 |
Observational Models:
Time Perspective List:
Who Masked List: